Compare FUSE & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUSE | ATNM |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | 270 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 42.0M |
| IPO Year | N/A | 2013 |
| Metric | FUSE | ATNM |
|---|---|---|
| Price | $1.41 | $1.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | ★ 149.6K | 108.9K |
| Earning Date | 06-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.80 | $0.95 |
| 52 Week High | $3.67 | $1.95 |
| Indicator | FUSE | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 45.53 | 45.36 |
| Support Level | $1.28 | $0.99 |
| Resistance Level | $1.50 | $1.25 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 26.32 | 8.70 |
Fusemachines Inc is a provider of enterprise AI solutions, offering products such as AI Studio, AI Engines, and AI Agents, along with supporting services across various industries. Its solutions are supported by a talent pool from underserved communities, enabling scalable and high-quality AI delivery while promoting access to AI. The Company serves clients across industries, including healthcare, media, technology, and government, helping address challenges such as improving forecasting accuracy, reducing data entry errors, automating recruitment, and detecting fraud. Its product suite includes AI Studio, AI Engines, and AI Agents, designed to build, deploy, and scale AI solutions, and it operates in Nepal and the United States.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.